Abstract
Kynurenine pathway (KP) is the primary path of tryptophan (Trp) catabolism in most mammalian cells. The KP generates several bioactive catabolites, such as kynurenine (Kyn), kynurenic acid (KA), 3-hydroxykynurenine (3-HK), xanthurenic acid (XA), and 3-hydroxyanthranilic acid (3-HAA). Increased catabolite concentrations in serum are associated with several cardiovascular diseases (CVD), including heart disease, atherosclerosis, and endothelial dysfunction, as well as their risk factors, including hypertension, diabetes, obesity, and aging. The first catabolic step in KP is primarily controlled by indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO). Following this first step, the KP has two major branches, one branch is mediated by kynurenine 3-monooxygenase (KMO) and kynureninase (KYNU) and is responsible for the formation of 3-HK, 3-HAA, and quinolinic acid (QA); and another branch is controlled by kynurenine amino-transferase (KAT), which generates KA. Uncontrolled Trp catabolism has been demonstrated in distinct CVD, thus, understanding the underlying mechanisms by which regulates KP enzyme expression and activity is paramount. This review highlights the recent advances on the effect of KP enzyme expression and activity in different tissues on the pathological mechanisms of specific CVD, KP is an inflammatory sensor and modulator in the cardiovascular system, and KP catabolites act as the potential biomarkers for CVD initiation and progression. Moreover, the biochemical features of critical KP enzymes and principles of enzyme inhibitor development are briefly summarized, as well as the therapeutic potential of KP enzyme inhibitors against CVD is briefly discussed.
Similar content being viewed by others
Abbreviations
- 1-MT:
-
1-methyl tryptophan
- 3-HAA:
-
3-hydroxyanthranilic acid
- 3-HK:
-
3-hydroxykynurenine
- AA:
-
Anthranilic acid
- AAA:
-
Abdominal aortic aneurysm
- AHR:
-
Aryl hydrocarbon receptor
- Ang II:
-
Angiotensin II
- DCs:
-
Dendritic cells
- HFD:
-
High-fat diet
- IDO1:
-
Indoleamine-2,3-dioxygenase 1
- IFN-γ:
-
Interferon-gamma
- IR:
-
Insulin resistance
- KA:
-
Kynurenic acid
- KAT:
-
Kynurenine amino-transferase
- KMO:
-
Kynurenine-3-monooxygenase
- KYNU:
-
Kynureninase
- KP:
-
Kynurenine pathway
- Kyn:
-
Kynurenine
- MMPs:
-
Matrix metalloproteinases
- oxLDL:
-
Oxidized low-density lipoprotein
- pDCs:
-
Plasmacytoid dendritic cells
- PLP:
-
Pyridoxal 5′-phosphate
- QA:
-
Quinolinic acid
- TDO:
-
Tryptophan 2,3-dioxygenase
- Trp:
-
Tryptophan
- VCAM-1:
-
Vascular cell adhesion molecule-1
- VSMC:
-
Vascular smooth muscle cell
- XA:
-
Xanthurenic acid
References
Polyzos KA, Ketelhuth DF (2015) The role of the kynurenine pathway of tryptophan metabolism in cardiovascular disease. An emerging field. Hamostaseologie 35:128–136
Jones SP, Franco NF, Varney B, Sundaram G, Brown DA, de Bie J, Lim CK, Guillemin GJ, Brew BJ (2015) Expression of the kynurenine pathway in human peripheral blood mononuclear cells: implications for inflammatory and neurodegenerative disease. PLoS One 10:e0131389
Guillemin GJ, Cullen KM, Lim CK, Smythe GA, Garner B, Kapoor V, Takikawa O, Brew BJ (2007) Characterization of the kynurenine pathway in human neurons. J Neurosci Off J Soc Neurosci 27:12884–12892
Giorgini F, Huang SY, Sathyasaikumar KV, Notarangelo FM, Thomas MA, Tararina M, Wu HQ, Schwarcz R, Muchowski PJ (2013) Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain. J Biol Chem 288:36554–36566
Prendergast GC, Metz R, Muller AJ, Merlo LM, Mandik-Nayak L (2014) IDO2 in Immunomodulation and Autoimmune Disease. Front Immunol 5:585
Phillips RS (2011) Structure, mechanism, and substrate specificity of kynureninase. Biochim Biophys Acta 1814:1481–1488
Campbell BM, Charych E, Lee AW, Moller T (2014) Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci 8:12
Breda C, Sathyasaikumar KV, Sograte Idrissi S, Notarangelo FM, Estranero JG, Moore GG, Green EW, Kyriacou CP, Schwarcz R, Giorgini F (2016) Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites. Proc Natl Acad Sci USA 113:5435–5440
Dounay AB, Tuttle JB, Verhoest PR (2015) Challenges and opportunities in the discovery of new therapeutics targeting the kynurenine pathway. J Med Chem 58:8762–8782
Platten M, Wick W, Van den Eynde BJ (2012) Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res 72:5435–5440
Larkin PB, Sathyasaikumar KV, Notarangelo FM, Funakoshi H, Nakamura T, Schwarcz R, Muchowski PJ (2016) Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice. Biochim Biophys Acta 1860:2345–2354
Ball HJ, Yuasa HJ, Austin CJ, Weiser S, Hunt NH (2009) Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int J Biochem Cell Biol 41:467–471
Fukunaga M, Yamamoto Y, Kawasoe M, Arioka Y, Murakami Y, Hoshi M, Saito K (2012) Studies on tissue and cellular distribution of indoleamine 2,3-dioxygenase 2: the absence of IDO1 upregulates IDO2 expression in the epididymis. J Histochem Cytochem 60:854–860
Lob S, Konigsrainer A, Zieker D, Brucher BL, Rammensee HG, Opelz G, Terness P (2009) IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother CII 58:153–157
Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC (2007) Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 67:7082–7087
Fujigaki H, Yamamoto Y, Saito K (2017) L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences. Neuropharmacology 112:264–274
Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 196:459–468
Matino D, Gargaro M, Santagostino E, Di Minno MN, Castaman G, Morfini M, Rocino A, Mancuso ME, Di Minno G, Coppola A, Talesa VN, Volpi C, Vacca C, Orabona C, Iannitti R, Mazzucconi MG, Santoro C, Tosti A, Chiappalupi S, Sorci G, Tagariello G, Belvini D, Radossi P, Landolfi R, Fuchs D, Boon L, Pirro M, Marchesini E, Grohmann U, Puccetti P, Iorio A, Fallarino F (2015) IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. J Clin Invest 125:3766–3781
Lima S, Kumar S, Gawandi V, Momany C, Phillips RS (2009) Crystal structure of the Homo sapiens kynureninase-3-hydroxyhippuric acid inhibitor complex: insights into the molecular basis of kynureninase substrate specificity. J Med Chem 52:389–396
Lovelace MD, Varney B, Sundaram G, Franco NF, Ng ML, Pai S, Lim CK, Guillemin GJ, Brew BJ (2016) Current evidence for a role of the kynurenine pathway of tryptophan metabolism in multiple sclerosis. Front Immunol 7:246
Adibfar A, Saleem M, Lanctot KL, Herrmann N (2016) Potential biomarkers for depression associated with coronary artery disease: a critical review. Curr Mol Med 16:137–164
Agudelo LZ, Femenia T, Orhan F, Porsmyr-Palmertz M, Goiny M, Martinez-Redondo V, Correia JC, Izadi M, Bhat M, Schuppe-Koistinen I, Pettersson AT, Ferreira DM, Krook A, Barres R, Zierath JR, Erhardt S, Lindskog M, Ruas JL (2014) Skeletal muscle PGC-1alpha1 modulates kynurenine metabolism and mediates resilience to stress-induced depression. Cell 159:33–45
Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G (2001) Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 313:96–98
Wonodi I, Schwarcz R (2010) Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. Schizophr Bull 36:211–218
Oxenkrug GF (2015) Increased plasma levels of xanthurenic and kynurenic acids in type 2 diabetes. Mol Neurobiol 52:805–810
Wainwright DA, Dey M, Chang A, Lesniak MS (2013) Targeting tregs in malignant brain cancer: overcoming IDO. Front Immunol 4:116
Munn DH, Mellor AL (2016) IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol 37:193–207
Wolf AM, Wolf D, Rumpold H, Moschen AR, Kaser A, Obrist P, Fuchs D, Brandacher G, Winkler C, Geboes K, Rutgeerts P, Tilg H (2004) Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. Clin Immunol 113:47–55
Wang Y, Liu H, McKenzie G, Witting PK, Stasch JP, Hahn M, Changsirivathanathamrong D, Wu BJ, Ball HJ, Thomas SR, Kapoor V, Celermajer DS, Mellor AL, Keaney JF Jr, Hunt NH, Stocker R (2010) Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med 16:279–285
Wang Q, Zhang M, Ding Y, Wang Q, Zhang W, Song P, Zou MH (2014) Activation of NAD(P)H oxidase by tryptophan-derived 3-hydroxykynurenine accelerates endothelial apoptosis and dysfunction in vivo. Circ Res 114:480–492
Mangge H, Stelzer I, Reininghaus EZ, Weghuber D, Postolache TT, Fuchs D (2014) Disturbed tryptophan metabolism in cardiovascular disease. Curr Med Chem 21:1931–1937
Platten M, von Knebel Doeberitz N, Oezen I, Wick W, Ochs K (2014) Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. Front Immunol 5:673
Wang Q, Liu D, Song P, Zou MH (2015) Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation. Front Biosci (Landmark edition) 20:1116–1143
Hansen AM, Driussi C, Turner V, Takikawa O, Hunt NH (2000) Tissue distribution of indoleamine 2,3-dioxygenase in normal and malaria-infected tissue. Redox Rep 5:112–115
Xiao Y, Christou H, Liu L, Visner G, Mitsialis SA, Kourembanas S, Liu H (2013) Endothelial indoleamine 2,3-dioxygenase protects against development of pulmonary hypertension. Am J Respir Crit Care Med 188:482–491
Niinisalo P, Oksala N, Levula M, Pelto-Huikko M, Jarvinen O, Salenius JP, Kytomaki L, Soini JT, Kahonen M, Laaksonen R, Hurme M, Lehtimaki T (2010) Activation of indoleamine 2,3-dioxygenase-induced tryptophan degradation in advanced atherosclerotic plaques: Tampere vascular study. Ann Med 42:55–63
Sakash JB, Byrne GI, Lichtman A, Libby P (2002) Cytokines induce indoleamine 2,3-dioxygenase expression in human atheroma-asociated cells: implications for persistent Chlamydophila pneumoniae infection. Infect Immun 70:3959–3961
Yun TJ, Lee JS, Machmach K, Shim D, Choi J, Wi YJ, Jang HS, Jung IH, Kim K, Yoon WK, Miah MA, Li B, Chang J, Bego MG, Pham TN, Loschko J, Fritz JH, Krug AB, Lee SP, Keler T, Guimond JV, Haddad E, Cohen EA, Sirois MG, El-Hamamsy I, Colonna M, Oh GT, Choi JH, Cheong C (2016) Indoleamine 2,3-dioxygenase-expressing aortic plasmacytoid dendritic cells protect against atherosclerosis by induction of regulatory T cells. Cell Metab 23:852–866
Munn DH, Mellor AL (2013) Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 34:137–143
Cuffy MC, Silverio AM, Qin L, Wang Y, Eid R, Brandacher G, Lakkis FG, Fuchs D, Pober JS, Tellides G (2007) Induction of indoleamine 2,3-dioxygenase in vascular smooth muscle cells by interferon-gamma contributes to medial immunoprivilege. J Immunol 179:5246–5254
Vecsei L, Szalardy L, Fulop F, Toldi J (2013) Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov 12:64–82
Zuo H, Ueland PM, Ulvik A, Eussen SJ, Vollset SE, Nygard O, Midttun O, Theofylaktopoulou D, Meyer K, Tell GS (2016) Plasma biomarkers of inflammation, the kynurenine pathway, and risks of all-cause, cancer, and cardiovascular disease mortality: the Hordaland health Study. Am J Epidemiol 183:249–258
Lowe MM, Mold JE, Kanwar B, Huang Y, Louie A, Pollastri MP, Wang C, Patel G, Franks DG, Schlezinger J, Sherr DH, Silverstone AE, Hahn ME, McCune JM (2014) Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 production. PLoS One 9:e87877
Sallee M, Dou L, Cerini C, Poitevin S, Brunet P, Burtey S (2014) The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease. Toxins (Basel) 6:934–949
Polyzos KA, Ovchinnikova O, Berg M, Baumgartner R, Agardh H, Pirault J, Gistera A, Assinger A, Laguna-Fernandez A, Back M, Hansson GK, Ketelhuth DF (2015) Inhibition of indoleamine 2,3-dioxygenase promotes vascular inflammation and increases atherosclerosis in Apoe−/− mice. Cardiovasc Res 106:295–302
Hayashi T, Mo JH, Gong X, Rossetto C, Jang A, Beck L, Elliott GI, Kufareva I, Abagyan R, Broide DH, Lee J, Raz E (2007) 3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis. Proc Natl Acad Sci USA 104:18619–18624
Wilson K, Auer M, Binnie M, Zheng X, Pham NT, Iredale JP, Webster SP, Mole DJ (2016) Overexpression of human kynurenine-3-monooxygenase protects against 3-hydroxykynurenine-mediated apoptosis through bidirectional nonlinear feedback. Cell Death Dis 7:e2197
Okuda S, Nishiyama N, Saito H, Katsuki H (1996) Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proc Natl Acad Sci USA 93:12553–12558
Eastman CL, Guilarte TR (1990) The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine. Neurochem Res 15:1101–1107
Oxenkrug G, van der Hart M, Summergrad P (2015) Elevated anthranilic acid plasma concentrations in type 1 but not type 2 diabetes mellitus. Integr Mol Med 2:365–368
Changsirivathanathamrong D, Wang Y, Rajbhandari D, Maghzal GJ, Mak WM, Woolfe C, Duflou J, Gebski V, dos Remedios CG, Celermajer DS, Stocker R (2011) Tryptophan metabolism to kynurenine is a potential novel contributor to hypotension in human sepsis. Crit Care Med 39:2678–2683
Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478:197–203
Oxenkrug GF, Turski WA, Zgrajka W, Weinstock JV, Summergrad P (2013) Tryptophan-kynurenine metabolism and insulin resistance in hepatitis C patients. Hepat Res Treat 149247
DiNatale BC, Murray IA, Schroeder JC, Flaveny CA, Lahoti TS, Laurenzana EM, Omiecinski CJ, Perdew GH (2010) Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci 115:89–97
Thomsen MS, Hansen HH, Timmerman DB, Mikkelsen JD (2010) Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr Pharm Des 16:323–343
Nilsen RM, Bjorke-Monsen AL, Midttun O, Nygard O, Pedersen ER, Ulvik A, Magnus P, Gjessing HK, Vollset SE, Ueland PM (2012) Maternal tryptophan and kynurenine pathway metabolites and risk of preeclampsia. Obstet Gynecol 119:1243–1250
Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H, Ling L (2006) Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 281:22021–22028
Haruki H, Hovius R, Pedersen MG, Johnsson K (2016) Tetrahydrobiopterin biosynthesis as a potential target of the kynurenine pathway metabolite xanthurenic acid. J Biol Chem 291:652–657
Malina HZ, Richter C, Mehl M, Hess OM (2001) Pathological apoptosis by xanthurenic acid, a tryptophan metabolite: activation of cell caspases but not cytoskeleton breakdown. BMC Physiol 1:7
Niinisalo P, Raitala A, Pertovaara M, Oja SS, Lehtimaki T, Kahonen M, Reunanen A, Jula A, Moilanen L, Kesaniemi YA, Nieminen MS, Hurme M (2008) Indoleamine 2,3-dioxygenase activity associates with cardiovascular risk factors: the Health 2000 study. Scand J Clin Lab Invest 68:767–770
Zhang L, Ovchinnikova O, Jonsson A, Lundberg AM, Berg M, Hansson GK, Ketelhuth DF (2012) The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice. Eur Heart J 33:2025–2034
Pawlak K, Mysliwiec M, Pawlak D (2010) Kynurenine pathway—a new link between endothelial dysfunction and carotid atherosclerosis in chronic kidney disease patients. Adv. Med Sci 55:196–203
Kato A, Suzuki Y, Suda T, Suzuki M, Fujie M, Takita T, Furuhashi M, Maruyama Y, Chida K, Hishida A (2010) Relationship between an increased serum kynurenine/tryptophan ratio and atherosclerotic parameters in hemodialysis patients. Hemodial Int 14:418–424
Pedersen ER, Tuseth N, Eussen SJ, Ueland PM, Strand E, Svingen GF, Midttun O, Meyer K, Mellgren G, Ulvik A, Nordrehaug JE, Nilsen DW, Nygard O (2015) Associations of plasma kynurenines with risk of acute myocardial infarction in patients with stable angina pectoris. Arterioscler Thromb Vasc Biol 35:455–462
Nikkheslat N, Zunszain PA, Horowitz MA, Barbosa IG, Parker JA, Myint AM, Schwarz MJ, Tylee AT, Carvalho LA, Pariante CM (2015) Insufficient glucocorticoid signaling and elevated inflammation in coronary heart disease patients with comorbid depression. Brain Behav Immun 48:8–18
Pedersen ER, Svingen GF, Schartum-Hansen H, Ueland PM, Ebbing M, Nordrehaug JE, Igland J, Seifert R, Nilsen RM, Nygard O (2013) Urinary excretion of kynurenine and tryptophan, cardiovascular events, and mortality after elective coronary angiography. Eur Heart J 34:2689–2696
Ormstad H, Verkerk R, Amthor KF, Sandvik L (2014) Activation of the kynurenine pathway in the acute phase of stroke and its role in fatigue and depression following stroke. J Mol Neurosci 54:181–187
Munipally PK, Agraharm SG, Valavala VK, Gundae S, Turlapati NR (2011) Evaluation of indoleamine 2,3-dioxygenase expression and kynurenine pathway metabolites levels in serum samples of diabetic retinopathy patients. Arch Physiol Biochem 117:254–258
Mudry JM, Alm PS, Erhardt S, Goiny M, Fritz T, Caidahl K, Zierath JR, Krook A, Wallberg-Henriksson H (2016) Direct effects of exercise on kynurenine metabolism in people with normal glucose tolerance or type 2 diabetes. Diabetes Metab Res Rev 32:754–761
Hattori M, Kotake Y, Kotake Y (1984) Studies on the urinary excretion of xanthurenic acid in diabetics. Acta Vitaminol Enzymol 6:221–228
Kapoor V, Kapoor R, Chalmers J (1994) Kynurenic acid, an endogenous glutamate antagonist, in SHR and WKY rats: possible role in central blood pressure regulation. Clin Exp Pharmacol Physiol 21:891–896
Ito S, Komatsu K, Tsukamoto K, Sved AF (2000) Excitatory amino acids in the rostral ventrolateral medulla support blood pressure in spontaneously hypertensive rats. Hypertension 35:413–417
Kwok JB, Kapoor R, Gotoda T, Iwamoto Y, Iizuka Y, Yamada N, Isaacs KE, Kushwaha VV, Church WB, Schofield PR, Kapoor V (2002) A missense mutation in kynurenine aminotransferase-1 in spontaneously hypertensive rats. J Biol Chem 277:35779–35782
Mangge H, Summers KL, Meinitzer A, Zelzer S, Almer G, Prassl R, Schnedl WJ, Reininghaus E, Paulmichl K, Weghuber D, Fuchs D (2014) Obesity-related dysregulation of the tryptophan-kynurenine metabolism: role of age and parameters of the metabolic syndrome. Obesity (Silver Spring) 22:195–201
Wolowczuk I, Hennart B, Leloire A, Bessede A, Soichot M, Taront S, Caiazzo R, Raverdy V, Pigeyre M, Consortium A, Guillemin GJ, Allorge D, Pattou F, Froguel P, Poulain-Godefroy O (2012) Tryptophan metabolism activation by indoleamine 2,3-dioxygenase in adipose tissue of obese women: an attempt to maintain immune homeostasis and vascular tone. Am J Physiol Regul Integr Comp Physiol 303:R135–R143
Ho JE, Larson MG, Ghorbani A, Cheng S, Chen MH, Keyes M, Rhee EP, Clish CB, Vasan RS, Gerszten RE, Wang TJ (2016) Metabolomic profiles of body mass index in the framingham heart study reveal distinct cardiometabolic phenotypes. PLoS One 11:e0148361
Favennec M, Hennart B, Caiazzo R, Leloire A, Yengo L, Verbanck M, Arredouani A, Marre M, Pigeyre M, Bessede A, Guillemin GJ, Chinetti G, Staels B, Pattou F, Balkau B, Allorge D, Froguel P, Poulain-Godefroy O (2015) The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation. Obesity (Silver Spring) 23:2066–2074
Mazarei G, Budac DP, Lu G, Adomat H, Tomlinson Guns ES, Moller T, Leavitt BR (2013) Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease. J Neurochem 127:852–867
Theofylaktopoulou D, Midttun O, Ulvik A, Ueland PM, Tell GS, Vollset SE, Nygard O, Eussen SJ (2013) A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study. Clin Exp Immunol 173:121–130
Capuron L, Schroecksnadel S, Feart C, Aubert A, Higueret D, Barberger-Gateau P, Laye S, Fuchs D (2011) Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry 70:175–182
Braidy N, Guillemin GJ, Mansour H, Chan-Ling T, Grant R (2011) Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged female Wistar rats. FEBS J 278:4425–4434
Pertovaara M, Raitala A, Juonala M, Lehtimaki T, Huhtala H, Oja SS, Jokinen E, Viikari JS, Raitakari OT, Hurme M (2007) Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the cardiovascular risk in young finns study. Clin Exp Immunol 148:106–111
Rassoulpour A, Wu HQ, Albuquerque EX, Schwarcz R (2005) Prolonged nicotine administration results in biphasic, brain-specific changes in kynurenate levels in the rat. Neuropsychopharmacology 30:697–704
Cole JE, Astola N, Cribbs AP, Goddard ME, Park I, Green P, Davies AH, Williams RO, Feldmann M, Monaco C (2015) Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development. Proc Natl Acad Sci USA 112:13033–13038
Stone TW, Darlington LG (2002) Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 1:609–620
Metghalchi S, Ponnuswamy P, Simon T, Haddad Y, Laurans L, Clement M, Dalloz M, Romain M, Esposito B, Koropoulis V, Lamas B, Paul JL, Cottin Y, Kotti S, Bruneval P, Callebert J, den Ruijter H, Launay JM, Danchin N, Sokol H, Tedgui A, Taleb S, Mallat Z (2015) Indoleamine 2,3-dioxygenase fine-tunes immune homeostasis in atherosclerosis and colitis through repression of interleukin-10 production. Cell Metab 22:460–471
Van de Velde LA, Gingras S, Pelletier S, Murray PJ (2016) Issues with the specificity of immunological reagents for murine IDO1. Cell Metab 23:389–390
Deanfield JE, Halcox JP, Rabelink TJ (2007) Endothelial function and dysfunction: testing and clinical relevance. Circulation 115:1285–1295
Song P, Zou MH (2014) Redox regulation of endothelial cell fate. Cell Mol Life Sci 71:3219–3239
Cai H, Harrison DG (2000) Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87:840–844
Santillan MK, Pelham CJ, Ketsawatsomkron P, Santillan DA, Davis DR, Devor EJ, Gibson-Corley KN, Scroggins SM, Grobe JL, Yang B, Hunter SK, Sigmund CD (2015) Pregnant mice lacking indoleamine 2,3-dioxygenase exhibit preeclampsia phenotypes. Physiol Rep 3:e12257
Barth MC, Ahluwalia N, Anderson TJ, Hardy GJ, Sinha S, Alvarez-Cardona JA, Pruitt IE, Rhee EP, Colvin RA, Gerszten RE (2009) Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions. J Biol Chem 284:19189–19195
Sekkai D, Guittet O, Lemaire G, Tenu JP, Lepoivre M (1997) Inhibition of nitric oxide synthase expression and activity in macrophages by 3-hydroxyanthranilic acid, a tryptophan metabolite. Arch Biochem Biophys 340:117–123
Fujigaki H, Saito K, Lin F, Fujigaki S, Takahashi K, Martin BM, Chen CY, Masuda J, Kowalak J, Takikawa O, Seishima M, Markey SP (2006) Nitration and inactivation of IDO by peroxynitrite. J Immunol 176:372–379
Wang YF, Hsu YJ, Wu HF, Lee GL, Yang YS, Wu JY, Yet SF, Wu KK, Kuo CC (2016) Endothelium-derived 5-methoxytryptophan is a circulating anti-inflammatory molecule that blocks systemic inflammation. Circ Res 119:222–236
Ho YC, Wu ML, Su CH, Chen CH, Ho HH, Lee GL, Lin WS, Lin WY, Hsu YJ, Kuo CC, Wu KK, Yet SF (2016) A novel protective function of 5-methoxytryptophan in vascular injury. Sci Rep 6:25374
Gold AB, Herrmann N, Swardfager W, Black SE, Aviv RI, Tennen G, Kiss A, Lanctot KL (2011) The relationship between indoleamine 2,3-dioxygenase activity and post-stroke cognitive impairment. J Neuroinflammation 8:17
Baran H, Amann G, Lubec B, Lubec G (1997) Kynurenic acid and kynurenine aminotransferase in heart. Pediatr Res 41:404–410
Ristagno G, Latini R, Vaahersalo J, Masson S, Kurola J, Varpula T, Lucchetti J, Fracasso C, Guiso G, Montanelli A, Barlera S, Gobbi M, Tiainen M, Pettila V, Skrifvars MB, Investigators F (2014) Early activation of the kynurenine pathway predicts early death and long-term outcome in patients resuscitated from out-of-hospital cardiac arrest. J Am Heart Assoc 3:e001094
Konishi M, Ebner N, Springer J, Schefold JC, Doehner W, Dschietzig TB, Anker SD, von Haehling S (2017) Impact of plasma kynurenine level on functional capacity and outcome in heart failure. Results From Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Circ J 81:52-+
Chang MY, Smith C, DuHadaway JB, Pyle JR, Boulden J, Soler AP, Muller AJ, Laury-Kleintop LD, Prendergast GC (2011) Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biol Ther 12:1050–1058
Silverstein MD, Pitts SR, Chaikof EL, Ballard DJ (2005) Abdominal aortic aneurysm (AAA): cost-effectiveness of screening, surveillance of intermediate-sized AAA, and management of symptomatic AAA. Proc (Bayl Univ Med Cent) 18:345–367
Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM (2011) Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol 8:92–102
Xiong W, MacTaggart J, Knispel R, Worth J, Persidsky Y, Baxter BT (2009) Blocking TNF-alpha attenuates aneurysm formation in a murine model. J Immunol 183:2741–2746
Golledge AL, Walker P, Norman PE, Golledge J (2009) A systematic review of studies examining inflammation associated cytokines in human abdominal aortic aneurysm samples. Dis Markers 26:181–188
Hellenthal FA, Buurman WA, Wodzig WK, Schurink GW (2009) Biomarkers of abdominal aortic aneurysm progression. Part 2: inflammation. Nat Rev Cardiol 6:543–552
Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S, Fishbein MC, Blaschke F, Kintscher U, Graf K, Law RE, Hsueh WA (2003) Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 112:1318–1331
Henderson EL, Geng YJ, Sukhova GK, Whittemore AD, Knox J, Libby P (1999) Death of smooth muscle cells and expression of mediators of apoptosis by T lymphocytes in human abdominal aortic aneurysms. Circulation 99:96–104
Abdul-Hussien H, Soekhoe RG, Weber E, von der Thusen JH, Kleemann R, Mulder A, van Bockel JH, Hanemaaijer R, Lindeman JH (2007) Collagen degradation in the abdominal aneurysm: a conspiracy of matrix metalloproteinase and cysteine collagenases. Am J Pathol 170:809–817
Davis FM, Rateri DL, Daugherty A (2014) Mechanisms of aortic aneurysm formation: translating preclinical studies into clinical therapies. Heart 100:1498–1505
Krettek A, Sukhova GK, Libby P (2003) Elastogenesis in human arterial disease: a role for macrophages in disordered elastin synthesis. Arterioscler Thromb Vasc Biol 23:582–587
Juvonen J, Surcel HM, Satta J, Teppo AM, Bloigu A, Syrjala H, Airaksinen J, Leinonen M, Saikku P, Juvonen T (1997) Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 17:2843–2847
Singh K, Bonaa KH, Jacobsen BK, Bjork L, Solberg S (2001) Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study: the Tromso study. Am J Epidemiol 154:236–244
Stackelberg O, Bjorck M, Sadr-Azodi O, Larsson SC, Orsini N, Wolk A (2013) Obesity and abdominal aortic aneurysm. Br J Surg 100:360–366
Police SB, Thatcher SE, Charnigo R, Daugherty A, Cassis LA (2009) Obesity promotes inflammation in periaortic adipose tissue and angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol 29:1458–1464
Folsom AR, Yao L, Alonso A, Lutsey PL, Missov E, Lederle FA, Ballantyne CM, Tang W (2015) Circulating biomarkers and abdominal aortic aneurysm incidence: the atherosclerosis risk in communities (ARIC) study. Circulation 132:578–585
De Haro J, Bleda S, Acin F (2016) C-reactive protein predicts aortic aneurysmal disease progression after endovascular repair. Int J Cardiol 202:701–706
De Haro J, Acin F, Bleda S, Varela C, Medina FJ, Esparza L (2012) Prediction of asymptomatic abdominal aortic aneurysm expansion by means of rate of variation of C-reactive protein plasma levels. J Vasc Surg 56:45–52
Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT (1995) Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 15:1145–1151
Thompson RW, Parks WC (1996) Role of matrix metalloproteinases in abdominal aortic aneurysms. Ann N Y Acad Sci 800:157–174
Li Y, Kilani RT, Rahmani-Neishaboor E, Jalili RB, Ghahary A (2014) Kynurenine increases matrix metalloproteinase-1 and -3 expression in cultured dermal fibroblasts and improves scarring in vivo. J Invest Dermatol 134:643–650
Poormasjedi-Meibod MS, Salimi Elizei S, Leung V, Baradar Jalili R, Ko F, Ghahary A (2016) Kynurenine modulates MMP-1 and type-I collagen expression via aryl hydrocarbon receptor activation in dermal fibroblasts. J Cell Physiol 231:2749–2760
Zhang C, van der Voort D, Shi H, Zhang R, Qing Y, Hiraoka S, Takemoto M, Yokote K, Moxon JV, Norman P, Rittie L, Kuivaniemi H, Atkins GB, Gerson SL, Shi GP, Golledge J, Dong N, Perbal B, Prosdocimo DA, Lin Z (2016) Matricellular protein CCN3 mitigates abdominal aortic aneurysm. J Clin Invest 126:1282–1299
Kudo Y, Boyd CA, Sargent IL, Redman CW (2003) Decreased tryptophan catabolism by placental indoleamine 2,3-dioxygenase in preeclampsia. Am J Obstet Gynecol 188:719–726
Bartosiewicz J, Kaminski T, Pawlak K, Karbowska M, Tankiewicz-Kwedlo A, Pawlak D (2017) The activation of the kynurenine pathway in a rat model with renovascular hypertension. Exp Biol Med 242. doi:10.1177/1535370217693114
Mizutani K, Sugimoto K, Okuda T, Katsuya T, Miyata T, Tanabe T, Higaki J, Ogihara T, Yamori Y, Tsujita Y, Tago N, Iwai N (2002) Kynureninase is a novel candidate gene for hypertension in spontaneously hypertensive rats. Hypertens Res 25:135–140
Zhang Y, Shen J, He X, Zhang K, Wu S, Xiao B, Zhou X, Phillips RS, Gao P, Jeunemaitre X, Zhu D (2011) A rare variant at the KYNU gene is associated with kynureninase activity and essential hypertension in the Han Chinese population. Circ Cardiovasc Genet 4:687–694
Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH, American Heart A, Obesity Committee of the Council on Nutrition PA, Metabolism (2006) Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 113:898–918
Boulet MM, Chevrier G, Grenier-Larouche T, Pelletier M, Nadeau M, Scarpa J, Prehn C, Marette A, Adamski J, Tchernof A (2015) Alterations of plasma metabolite profiles related to adipose tissue distribution and cardiometabolic risk. Am J Physiol Endocrinol Metab 309:E736–E746
Favennec M, Hennart B, Verbanck M, Pigeyre M, Caiazzo R, Raverdy V, Verkindt H, Leloire A, Guillemin GJ, Yengo L, Allorge D, Froguel P, Pattou F, Poulain-Godefroy O (2016) Post-bariatric surgery changes in quinolinic and xanthurenic acid concentrations are associated with glucose homeostasis. PLoS One 11:e0158051
Moyer BJ, Rojas IY, Kerley-Hamilton JS, Hazlett HF, Nemani KV, Trask HW, West RJ, Lupien LE, Collins AJ, Ringelberg CS, Gimi B, Kinlaw WB 3rd, Tomlinson CR (2016) Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGFbeta, and IDO1. Toxicol Appl Pharmacol 300:13–24
Watts SW, Shaw S, Burnett R, Dorrance AM (2011) Indoleamine 2,3-diooxygenase in periaortic fat: mechanisms of inhibition of contraction. Am J Physiol Heart Circ Physiol 301:H1236–H1247
Laakso M (2010) Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care 33:442–449
Oxenkrug G (2013) Insulin resistance and dysregulation of tryptophan-kynurenine and kynurenine-nicotinamide adenine dinucleotide metabolic pathways. Mol Neurobiol 48:294–301
Navrotskaya V, Oxenkrug G, Vorobyova L, Summergrad P (2015) Attenuation of high sucrose diet-induced insulin resistance in tryptophan 2,3-dioxygenase deficient Drosophila melanogaster vermilion mutants. Integr Obes. Diabetes 1:93–95
Ahmadou MA, JOHA MS (2015) Kynurenine-modified serum proteins are a new marker of cardiovascular discorders developing in type 2 diabetes. Int J Acad Sci Res 3:101–105
Koopmans SJ, Ruis M, Dekker R, Korte M (2009) Surplus dietary tryptophan inhibits stress hormone kinetics and induces insulin resistance in pigs. Physiol Behav 98:402–410
Oxenkrug G (2011) Interferon-gamma—inducible inflammation: contribution to aging and aging-associated psychiatric disorders. Aging Dis 2:474–486
van der Goot AT, Zhu W, Vazquez-Manrique RP, Seinstra RI, Dettmer K, Michels H, Farina F, Krijnen J, Melki R, Buijsman RC, Ruiz Silva M, Thijssen KL, Kema IP, Neri C, Oefner PJ, Nollen EA (2012) Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation. Proc Natl Acad Sci USA 109:14912–14917
Deac OM, Mills JL, Shane B, Midttun O, Ueland PM, Brosnan JT, Brosnan ME, Laird E, Gibney ER, Fan R, Wang Y, Brody LC, Molloy AM (2015) Tryptophan catabolism and vitamin B-6 status are affected by gender and lifestyle factors in healthy young adults. J Nutr 145:701–707
Ulvik A, Theofylaktopoulou D, Midttun O, Nygard O, Eussen SJ, Ueland PM (2013) Substrate product ratios of enzymes in the kynurenine pathway measured in plasma as indicators of functional vitamin B-6 status. Am J Clin Nutr 98:934–940
Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191–1193
Cady SG, Sono M (1991) 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys 291:326–333
Study of chemotherapy in combination with IDO inhibitor in metastatic breast cancer. http://www.https://clinicaltrialsgov/show/NCT01792050. Accessed 24 October 2016
Immunotherapy combination study in advanced previously treated non-small cell lung cancer. http://www.https://clinicaltrialsgov/show/NCT02460367. Accessed 24 October 2016
Phase II INCB024360 study for patients with myelodysplastic syndromes (MDS). http://www.https://clinicaltrialsgov/show/NCT01822691. Accessed 24 October 2016
Peng YH, Ueng SH, Tseng CT, Hung MS, Song JS, Wu JS, Liao FY, Fan YS, Wu MH, Hsiao WC, Hsueh CC, Lin SY, Cheng CY, Tu CH, Lee LC, Cheng MF, Shia KS, Shih C, Wu SY (2016) Important hydrogen bond networks in indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor design revealed by crystal structures of imidazoleisoindole derivatives with IDO1. J Med Chem 59:282–293
Indoleamine 2,3-Dioxygenase (IDO) inhibitor in advanced solid tumors. http://www.https://clinicaltrialsgov/show/NCT02048709. Accessed 24 October 2016
IDO peptid vaccination for stage III-IV non small-cell lung cancer patients. (IDOvaccine). http://www.https://clinicaltrialsgov/show/NCT01219348. Accessed 24 October 2016
Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, Leffet L, Hansbury MJ, Thomas B, Rupar M, Waeltz P, Bowman KJ, Polam P, Sparks RB, Yue EW, Li Y, Wynn R, Fridman JS, Burn TC, Combs AP, Newton RC, Scherle PA (2010) Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115:3520–3530
Koblish HK, Hansbury MJ, Bowman KJ, Yang G, Neilan CL, Haley PJ, Burn TC, Waeltz P, Sparks RB, Yue EW, Combs AP, Scherle PA, Vaddi K, Fridman JS (2010) Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther 9:489–498
Kumar S, Jaller D, Patel B, LaLonde JM, DuHadaway JB, Malachowski WP, Prendergast GC, Muller AJ (2008) Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem 51:4968–4977
Li M, Bolduc AR, Hoda MN, Gamble DN, Dolisca SB, Bolduc AK, Hoang K, Ashley C, McCall D, Rojiani AM, Maria BL, Rixe O, MacDonald TJ, Heeger PS, Mellor AL, Munn DH, Johnson TS (2014) The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother. Cancer 2:21
Mole DJ, Webster SP, Uings I, Zheng X, Binnie M, Wilson K, Hutchinson JP, Mirguet O, Walker A, Beaufils B, Ancellin N, Trottet L, Beneton V, Mowat CG, Wilkinson M, Rowland P, Haslam C, McBride A, Homer NZ, Baily JE, Sharp MG, Garden OJ, Hughes J, Howie SE, Holmes DS, Liddle J, Iredale JP (2016) Kynurenine-3-monooxygenase inhibition prevents multiple organ failure in rodent models of acute pancreatitis. Nat Med 22:202–209
Rover S, Cesura AM, Huguenin P, Kettler R, Szente A (1997) Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem 40:4378–4385
Amaral M, Levy C, Heyes DJ, Lafite P, Outeiro TF, Giorgini F, Leys D, Scrutton NS (2013) Structural basis of kynurenine 3-monooxygenase inhibition. Nature 496:382–385
Chiarugi A, Carpenedo R, Molina MT, Mattoli L, Pellicciari R, Moroni F (1995) Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase. J Neurochem 65:1176–1183
Walsh HA, Leslie PL, O’Shea KC, Botting NP (2002) 2-Amino-4-[3′-hydroxyphenyl]-4-hydroxybutanoic acid; a potent inhibitor of rat and recombinant human kynureninase. Bioorganic medicinal chemistry letters 12:361–363
Kasper SH, Bonocora RP, Wade JT, Musah RA, Cady NC (2016) Chemical inhibition of kynureninase reduces pseudomonas aeruginosa quorum sensing and virulence factor expression. ACS Chem Biol 11:1106–1117
Dounay AB, Anderson M, Bechle BM, Campbell BM, Claffey MM, Evdokimov A, Evrard E, Fonseca KR, Gan X, Ghosh S, Hayward MM, Horner W, Kim JY, McAllister LA, Pandit J, Paradis V, Parikh VD, Reese MR, Rong S, Salafia MA, Schuyten K, Strick CA, Tuttle JB, Valentine J, Wang H, Zawadzke LE, Verhoest PR (2012) Discovery of brain-penetrant, irreversible kynurenine aminotransferase II inhibitors for schizophrenia. ACS Med Chem Lett 3:187–192
Rossi F, Valentina C, Garavaglia S, Sathyasaikumar KV, Schwarcz R, Kojima S, Okuwaki K, Ono S, Kajii Y, Rizzi M (2010) Crystal structure-based selective targeting of the pyridoxal 5′-phosphate dependent enzyme kynurenine aminotransferase II for cognitive enhancement. J Med Chem 53:5684–5689
Amori L, Guidetti P, Pellicciari R, Kajii Y, Schwarcz R (2009) On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J Neurochem 109:316–325
Rohrig UF, Majjigapu SR, Vogel P, Zoete V, Michielin O (2015) Challenges in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. J Med Chem 58:9421–9437
Yue EW, Douty B, Wayland B, Bower M, Liu X, Leffet L, Wang Q, Bowman KJ, Hansbury MJ, Liu C, Wei M, Li Y, Wynn R, Burn TC, Koblish HK, Fridman JS, Metcalf B, Scherle PA, Combs AP (2009) Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J Med Chem 52:7364–7367
Sugimoto H, Oda S, Otsuki T, Hino T, Yoshida T, Shiro Y (2006) Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci USA 103:2611–2616
Tojo S, Kohno T, Tanaka T, Kamioka S, Ota Y, Ishii T, Kamimoto K, Asano S, Isobe Y (2014) Crystal structures and structure-activity relationships of imidazothiazole derivatives as IDO1 inhibitors. ACS Med Chem Lett 5:1119–1123
Alvarez L, Lewis-Ballester A, Roitberg A, Estrin DA, Yeh SR, Marti MA, Capece L (2016) Structural study of a flexible active site loop in human indoleamine 2,3-dioxygenase and its functional implications. BioChemistry 55:2785–2793
Fujigaki H, Seishima M, Saito K (2012) Posttranslational modification of indoleamine 2,3-dioxygenase. Anal Bioanal Chem 403:1777–1782
Qian S, He T, Wang W, He Y, Zhang M, Yang L, Li G, Wang Z (2016) Discovery and preliminary structure-activity relationship of 1H-indazoles with promising indoleamine-2,3-dioxygenase 1 (IDO1) inhibition properties. Bioorg Med Chem 24:6194–6205
Malachowski WP, Winters M, DuHadaway JB, Lewis-Ballester A, Badir S, Wai J, Rahman M, Sheikh E, LaLonde JM, Yeh SR, Prendergast GC, Muller AJ (2016) O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1. Eur J Med Chem 108:564–576
Pantouris G, Serys M, Yuasa HJ, Ball HJ, Mowat CG (2014) Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1. Amino Acids 46:2155–2163
Meininger D, Zalameda L, Liu Y, Stepan LP, Borges L, McCarter JD, Sutherland CL (2011) Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors. Biochim Biophys Acta 1814:1947–1954
Smith JR, Jamie JF, Guillemin GJ (2016) Kynurenine-3-monooxygenase: a review of structure, mechanism, and inhibitors. Drug Discov Today 21:315–324
Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ, Lee J, Truong J, Andrews-Zwilling Y, Hsieh EW, Louie JY, Wu T, Scearce-Levie K, Patrick C, Adame A, Giorgini F, Moussaoui S, Laue G, Rassoulpour A, Flik G, Huang Y, Muchowski JM, Masliah E, Schwarcz R, Muchowski PJ (2011) Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145:863–874
Stone TW, Forrest CM, Darlington LG (2012) Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection. FEBS J 279:1386–1397
Rojewska E, Piotrowska A, Makuch W, Przewlocka B, Mika J (2016) Pharmacological kynurenine 3-monooxygenase enzyme inhibition significantly reduces neuropathic pain in a rat model. Neuropharmacology 102:80–91
Fitzgerald DH, Muirhead KM, Botting NP (2001) A comparative study on the inhibition of human and bacterial kynureninase by novel bicyclic kynurenine analogues. Bioorg Med Chem 9:983–989
Phillips RS (2014) Structure and mechanism of kynureninase. Arch Biochem Biophys 544:69–74
Han Q, Cai T, Tagle DA, Li J (2010) Structure, expression, and function of kynurenine aminotransferases in human and rodent brains. Cell Mol Life Sci 67:353–368
Sun G, Nematollahi A, Nadvi NA, Kwan AH, Jeffries CM, Church WB (2016) Expression, purification and crystallization of human kynurenine aminotransferase 2 exploiting a highly optimized codon set. Protein Expr Purif 121:41–45
Koola MM (2016) Kynurenine pathway and cognitive impairments in schizophrenia: pharmacogenetics of galantamine and memantine. Schizophr Res Cogn 4:4–9
Yu P, Li Z, Zhang L, Tagle DA, Cai T (2006) Characterization of kynurenine aminotransferase III, a novel member of a phylogenetically conserved KAT family. Gene 365:111–118
Han Q, Robinson H, Cai T, Tagle DA, Li J (2011) Biochemical and structural characterization of mouse mitochondrial aspartate aminotransferase, a newly identified kynurenine aminotransferase-IV. Biosci Rep 31:323–332
Guidetti P, Amori L, Sapko MT, Okuno E, Schwarcz R (2007) Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J Neurochem 102:103–111
Schlittler M, Goiny M, Agudelo LZ, Venckunas T, Brazaitis M, Skurvydas A, Kamandulis S, Ruas JL, Erhardt S, Westerblad H, Andersson DC (2016) Endurance exercise increases skeletal muscle kynurenine aminotransferases and plasma kynurenic acid in humans. Am J Physiol Cell Physiol 310:C836–C840
Han Q, Robinson H, Li J (2008) Crystal structure of human kynurenine aminotransferase II. J Biol Chem 283:3567–3573
Nematollahi A, Sun G, Harrop SJ, Hanrahan JR, Church WB (2016) Structure of the PLP-form of the human kynurenine aminotransferase II in a novel spacegroup at 1.83 A resolution. Int J Mol Sci 17:446
Nematollahi A, Sun G, Jayawickrama GS, Church WB (2016) Kynurenine aminotransferase isozyme inhibitors: a review. Int J Mol Sci 17:946
Acknowledgements
This study was supported by funding from the following agencies: National Institutes of Health RO1 (HL132500, HL128014, HL110488, HL080499, HL089920, AG047776, and CA213022). This work is in part supported by the Georgia Research Alliance. Dr. Zou is a Georgia Research Alliance Eminent Scholar in Molecular Medicine.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there are no conflicts of interest.
Rights and permissions
About this article
Cite this article
Song, P., Ramprasath, T., Wang, H. et al. Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases. Cell. Mol. Life Sci. 74, 2899–2916 (2017). https://doi.org/10.1007/s00018-017-2504-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-017-2504-2